How to access Fabhalta from Saudi Arabia, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient with paroxysmal nocturnal hemoglobinuria (PNH) may be evaluated by their treating haematologist for Fabhalta (iptacopan). Fabhalta is FDA-approved in the United States and manufactured by Novartis. It is the first oral monotherapy for PNH and a first-in-class factor B inhibitor, acting on the alternative complement pathway. Fabhalta is rarely locally registered outside the US and EU, and for Saudi patients the named-patient import pathway via Saudi Arabia Ministry of Public Health (MoPH) is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Fabhalta is administered as an oral capsule twice daily. It targets factor B in the alternative complement pathway, addressing both intravascular and extravascular haemolysis. Like other complement pathway inhibitors, it carries a US class-level warning about encapsulated-organism infections; vaccination (meningococcus, pneumococcus, Hib) is a gating step before therapy. Your treating haematologist confirms PNH diagnosis (flow cytometry), prior therapy history, vaccination completion, and the monitoring plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Fabhalta legally importable into Saudi Arabia?
Yes, through Saudi Arabia Ministry of Public Health (MoPH) Pharmacy & Drug Control Department named-patient framework. The pathway allows a Saudi Arabia-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
For oral complement-pathway inhibitors, the named-patient route is the standard mechanism in Saudi tertiary haematology, Fabhalta is not yet on a local formulary.
How the pathway works, step by step
- Consultation with your treating haematologist. PNH flow cytometry confirmation, prior therapy history, and clinical rationale.
- Pre-treatment vaccination. Meningococcal, pneumococcal, and Hib vaccinations per labeling.
- MoPH named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Shipment. Fabhalta is an oral capsule with standard storage; shipment includes tamper-evident packaging and chain-of-custody documentation.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming PNH, diagnostic evidence (flow cytometry), prior therapies, and Fabhalta as the indicated treatment
- Verification of their Saudi Arabia medical licence
- Patient identifier
- Vaccination documentation
- Planned twice-daily oral regimen and monitoring cadence
Reserve Meds provides a physician documentation kit that bundles the templates MoPH reviewers expect to see for complement-pathway inhibitors.
Costs and timing
Fabhalta's US cash-pay drug-only reference price for a 30-day supply sits in a broad indicative range of roughly USD 38,000-45,000. International logistics, MoPH documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. Indicative range.
Indicative timing for first dose after cohort intake opens is 7-14 days from the moment a complete application is submitted, plus vaccination lead time. Refills ship on a rolling basis.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Fabhalta specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoPH review.
- Logistics. Tamper-evident, internationally tracked shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the MoPH named-patient framework with appropriate documentation.
Why Fabhalta rather than a C5 or C3 inhibitor? Fabhalta's oral route is a major quality-of-life factor, no infusions or subcutaneous injections. Efficacy data support its use as monotherapy in PNH, including in patients with persistent anaemia on C5 inhibition. Your haematologist will decide.
What about the vaccination requirement? It is load-bearing. Encapsulated-organism vaccination per labeling is completed before therapy starts.
Will private insurance cover this? Cash-pay is the default. Some Saudi insurers reimburse named-patient imports for ultra-rare-disease therapies on escalated review; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Fabhalta coordination in Saudi Arabia, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.
Regulatory status of Fabhalta (iptacopan) in Saudi Arabia, 2026
Fabhalta (iptacopan) is approved by the US Food and Drug Administration for the labelled indication of paroxysmal nocturnal hemoglobinuria and complement-mediated kidney disease (C3G, IgA nephropathy in adults) (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a Saudi Arabia-based patient, the access pathway runs through the Saudi Food and Drug Authority (SFDA) framework. The official regulator portal is at www.sfda.gov.sa/en; the locally registered medicines list is at www.sfda.gov.sa/en/drugs-list.
Where Fabhalta (iptacopan) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Fabhalta (iptacopan) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Saudi Food and Drug Authority (SFDA) maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Fabhalta (iptacopan) case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah, King Abdulaziz Medical City (KAMC), King Fahad Medical City (KFMC), Princess Noorah Oncology Center, and King Fahd Specialist Hospital Dammam. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For oral selective factor B inhibitor of the alternative complement pathway therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For oral, subcutaneous, or in-clinic infusion therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into Saudi Arabia; the Saudi Arabia tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
Saudi Arabia pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for SAR conversion is 1 USD = 3.750 SAR. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only cost for Fabhalta (iptacopan) reflects the US wholesale acquisition cost published by the manufacturer (Novartis) plus standard specialty pharmacy markup; the precise band is delivered in the case quote because it varies by indication, dosing, and pack size.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost commonly lands meaningfully above the drug-only band once treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics are added in.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is CCHI (Council of Cooperative Health Insurance); the portal is at www.cchi.gov.sa. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Fabhalta (iptacopan) case in Saudi Arabia are: (1) Regulatory documentation complexity. The Saudi Food and Drug Authority (SFDA) named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Fabhalta (iptacopan) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Fabhalta (iptacopan): the labelled indication is paroxysmal nocturnal hemoglobinuria and complement-mediated kidney disease (C3G, IgA nephropathy in adults). The oral selective factor B inhibitor of the alternative complement pathway mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is International PNH Interest Group and the Kidney Disease: Improving Global Outcomes (KDIGO) glomerular diseases guidelines at kdigo.org/guidelines/. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Fabhalta (iptacopan) in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en and the locally registered medicines list at www.sfda.gov.sa/en/drugs-list are the authoritative source for the current Saudi Arabia listing status of Fabhalta (iptacopan); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Fabhalta (iptacopan) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Fabhalta (iptacopan) remains paroxysmal nocturnal hemoglobinuria and complement-mediated kidney disease (C3G, IgA nephropathy in adults) (see the current FDA approval record at accessdata.fda.gov). Novartis continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The International PNH Interest Group and the Kidney Disease: Improving Global Outcomes (KDIGO) glomerular diseases guidelines guidance at kdigo.org/guidelines/ remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.